Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis

Evaluating osteoporotic fracture risk with the Fracture Risk Assessment Tool in Chinese patients with rheumatoid arthritis

(2017) Juan Meng et al.   MEDICINE

Anti-citrullinated protein antibodies are associated with decreased bone mineral density: baseline data from a register of early arthritis patients

(2017) Irene Llorente et al.   RHEUMATOLOGY INTERNATIONAL

Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis

(2016) A. Balasubramanian et al.   OSTEOPOROSIS INTERNATIONAL

Biologic therapies and bone loss in rheumatoid arthritis

(2016) C. A. F. Zerbini et al.   OSTEOPOROSIS INTERNATIONAL

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review

(2016) Emilio Martin-Mola et al.   RHEUMATOLOGY INTERNATIONAL

The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis

(2015) Karine Briot et al.   JOINT BONE SPINE

Bone mineral density of postmenopausal women with rheumatoid arthritis depends on disease duration regardless of treatment

(2015) Yu Mori et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Evolutionary medicine and bone loss in chronic inflammatory diseases—A theory of inflammation-related osteopenia

(2015) Rainer H. Straub et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Meta-Analysis of Tumor Necrosis Factor Inhibitors and Glucocorticoids on Bone Density in Rheumatoid Arthritis and Ankylosing Spondylitis Trials

(2015) Stephanie Siu et al.   ARTHRITIS CARE & RESEARCH

Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study

(2014) Jun Hashimoto et al.   Modern Rheumatology

Rheumatoid arthritis patients with hip fracture: a nationwide study

(2014) Y.-C. Lin et al.   OSTEOPOROSIS INTERNATIONAL

The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis

(2014) K. Kume et al.   RHEUMATOLOGY

Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model

(2013) Keisuke Tanaka et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The prevalence of vertebral fracture on vertebral fracture assessment imaging in a large cohort of patients with rheumatoid arthritis

(2013) A. Mohammad et al.   RHEUMATOLOGY

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study

(2012) Stephanie Finzel et al.   ANNALS OF THE RHEUMATIC DISEASES

Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin

(2012) Ulrike Harre et al.   JOURNAL OF CLINICAL INVESTIGATION

Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?

(2012) M. C. van der Goes et al.   OSTEOPOROSIS INTERNATIONAL

Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study

(2012) C. L. M. Krieckaert et al.   RHEUMATOLOGY

Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage

(2012) Mona Helmy Abdel Meguid et al.   RHEUMATOLOGY INTERNATIONAL

IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)

(2012) Morten A. Karsdal et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Initiation of Tumor Necrosis Factor α Antagonists and Risk of Fractures in Patients With Selected Rheumatic and Autoimmune Diseases

(2012) Vivian K. Kawai et al.   ARTHRITIS CARE & RESEARCH

Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population-based cohort study

(2011) Seo Young Kim et al.   JOURNAL OF BONE AND MINERAL RESEARCH

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis

(2010) C. J. Edwards et al.   OSTEOPOROSIS INTERNATIONAL

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss

(2008) C A Wijbrandts et al.   ANNALS OF THE RHEUMATIC DISEASES

Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis

(2008) C. Book et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY